Charles River Laboratories
664 hedge funds and large institutions have $10.8B invested in Charles River Laboratories in 2024 Q2 according to their latest regulatory filings, with 74 funds opening new positions, 266 increasing their positions, 235 reducing their positions, and 79 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 266 | Existing positions reduced: 235
0.06% less ownership
Funds ownership: 101.79% → 101.73% (-0.06%)
6% less first-time investments, than exits
New positions opened: 74 | Existing positions closed: 79
2% less funds holding
Funds holding: 676 → 664 (-12)
15% less call options, than puts
Call options by funds: $54.2M | Put options by funds: $63.4M
23% less capital invested
Capital invested by funds: $14.1B → $10.8B (-$3.32B)
47% less funds holding in top 10
Funds holding in top 10: 15 → 8 (-7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
Southpoint Capital Advisors
New York
|
+$102M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$36.9M |
| 3 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$36.3M |
| 4 |
MDSL
M.D. Sass LLC
New York
|
+$36.1M |
| 5 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$30.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$154M |
| 2 |
MBI
Montrusco Bolton Investments
Montreal,
Quebec, Canada
|
-$133M |
| 3 |
William Blair Investment Management
Chicago,
Illinois
|
-$98.8M |
| 4 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$43.3M |
| 5 |
ClearBridge Investments
New York
|
-$32.8M |
CRL Hedge Fund Activity: Q2 2024 in Review
664 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q2 2024, worth a combined $10.8B — down 23% from $14.1B a quarter earlier.
Sellers outnumbered buyers: 79 funds closed out of CRL and 74 opened new positions — a net loss of 5 holders — while 235 trimmed existing stakes and 266 added.
The largest buyer was Southpoint Capital Advisors, adding an estimated $102M. The largest seller was T. Rowe Price Associates, cutting an estimated $154M.
- 664 institutional investors held Charles River Laboratories (CRL) as of Q2 2024, down from 676 in Q1 2024.
- Funds reported $10.8B of Charles River Laboratories stock for Q2 2024, down 23% quarter-over-quarter.
- 74 funds opened new Charles River Laboratories positions in Q2 2024 and 79 closed out, a net change of -5 holders.
- The largest Charles River Laboratories buyer in Q2 2024 was Southpoint Capital Advisors, an estimated $102M added.
- The largest Charles River Laboratories seller in Q2 2024 was T. Rowe Price Associates, an estimated $154M sold.
Based on aggregated 13F filings for Q2 2024.